Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022

Overview of attention for article published in Expert Opinion on Drug Discovery, February 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

So far, Altmetric has seen 16 X posts from 16 X users, with an upper bound of 7,640 followers.

RT @sharpie510: "...(DCVax-L) seems to be a really promising immunotherapeutic agent, having shown great efficacy in prolonging survival an…

RT @sharpie510: "...(DCVax-L) seems to be a really promising immunotherapeutic agent, having shown great efficacy in prolonging survival an…

RT @sharpie510: "...(DCVax-L) seems to be a really promising immunotherapeutic agent, having shown great efficacy in prolonging survival an…

RT @sharpie510: "...(DCVax-L) seems to be a really promising immunotherapeutic agent, having shown great efficacy in prolonging survival an…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 12 additional X posts.